CorMedix (CRMD)

• Market cap: $520M
• 1 day: -3.38%
• 5 days: 2.39%
• 1 month: -20.20%
• 3 months: 16.12%
• 6 months: 93.45%
• Year to date: 127.32%
• 1 year: 146.97%
• 5 years: 14.88%
• 10 years: 19.86%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.

Employees: 82

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

104% more capital invested

Capital invested by funds: $75.5M [Q2] → $154M (+$78.9M) [Q3]

100% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 2 (+1) [Q3]

61% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 23

19% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 16

3% more funds holding

Funds holding: 99 [Q2] → 102 (+3) [Q3]

2.51% more ownership

Funds ownership: 31.72% [Q2] → 34.23% (+2.51%) [Q3]

70% less call options, than puts

Call options by funds: $1.08M | Put options by funds: $3.57M

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 40% upside
• Avg. target: $15.67 83% upside
• High target: $18 110% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

RBC Capital Gregory Renza 40% 1-year accuracy 32 / 81 met price target	40% upside $12	Outperform Maintained	19 Dec 2024
Needham Serge Belanger 40% 1-year accuracy 50 / 126 met price target	110% upside $18	Buy Maintained	31 Oct 2024
Truist Securities Joon Lee 47% 1-year accuracy 17 / 36 met price target	98% upside $17	Buy Maintained	22 Oct 2024